XTLB XTL Biopharmaceuticals Ltd. Stock Quote

XTLB [NASD]

Index	-	P/E	-	EPS (ttm)	-0.15	Insider Own	1.00%	Shs Outstand	5.14M	Perf Week	-14.22%
Market Cap	17.44M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.49M	Perf Month	-5.57%
Income	-0.80M	PEG	-	EPS next Q	-	Inst Own	9.70%	Short Float	0.90%	Perf Quarter	0.00%
Sales	-	P/S	-	EPS this Y	42.00%	Inst Trans	-	Short Ratio	0.34	Perf Half Y	10.56%
Book/sh	1.22	P/B	2.92	EPS next Y	-	ROA	-	Target Price	-	Perf Year	118.40%
Cash/sh	1.22	P/C	2.91	EPS next 5Y	-	ROE	-	52W Range	1.44 - 6.69	Perf YTD	17.49%
Dividend	-	P/FCF	-	EPS past 5Y	35.60%	ROI	-	52W High	-47.68%	Beta	1.05
Dividend %	-	Quick Ratio	24.10	Sales past 5Y	-	Gross Margin	-	52W Low	143.04%	ATR	0.48
Employees	-	Current Ratio	24.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	45.68	Volatility	24.45% 12.18%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	118.50%	Profit Margin	-	Rel Volume	0.99	Prev Close	3.56
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	92.97K	Price	3.50
Recom	-	SMA20	-5.82%	SMA50	-2.82%	SMA200	9.88%	Volume	62,366	Change	-1.69%

May-08-15

Initiated

H.C. Wainwright

Buy

Nov-21-18 08:00AM	Consolidated Research: 2018 Summary Expectations for Discovery, Focus Financial Partners, Art's-Way Manufacturing Co., Digital Ally, US Gold, and XTL Biopharmaceuticals Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-01-18 10:09AM	XTL Biopharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Update PR Newswire -10.32%
Jul-24-18 09:09AM	XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides Update PR Newswire
May-29-18 05:37PM	XTL Biopharmaceuticals Reports First Quarter 2018 Financial Results & Provides Update PR Newswire
Dec-13-17 07:30AM	Wired News Medigene Announced Collaboration with RXi Pharma to Further Improve its Therapeutic T Cells ACCESSWIRE
Dec-06-17 12:08PM	XTL Biopharmaceuticals Ltd. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements PR Newswire
Nov-27-17 10:30AM	XTL Biopharmaceuticals Reports Third Quarter 2017 Financial Results PR Newswire
Oct-23-17 11:23AM	XTL Biopharmaceuticals Receives Notification From NASDAQ Regarding Continuing Listing Requirements PR Newswire
Oct-06-17 07:30AM	Corporate News Blog - Catabasis Pharma Shares Positive Results from Phase-2 MoveDMD Trials for Assessing Edasalonexent for Treatment of Duchenne Muscular Dystrophy ACCESSWIRE
Oct-05-17 07:50AM	Earnings Review and Free Research Report: DelMar Missed Earnings Expectations ACCESSWIRE
Sep-26-17 09:23AM	XTL Biopharmaceuticals Reports First Half 2017 Financial Results & Provides Clinical and Operational Update PR Newswire
Sep-12-17 09:00AM	XTL Biopharmaceuticals Unveils Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's Syndrome PR Newswire
Jul-11-17 07:00AM	Featured Company News Inotek Pharma Announces Top-line Results of Phase-2 FDC Trial of Trabodenoson and Offers Corporate Update Accesswire
Jun-15-17 09:00AM	XTL Biopharmaceuticals Reports First Quarter 2017 Financial Results & Provides Clinical and Operational Update PR Newswire
Apr-27-17 09:50AM	XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of Directors PR Newswire
Apr-05-17 09:10AM	XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögrens Syndrome PR Newswire
09:10AM	XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögrens Syndrome
Mar-30-17 08:55AM	XTL Biopharmaceuticals Reports 2016 Financial Results & Provides Clinical and Operational Update PR Newswire
Mar-22-17 09:22AM	XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing Investors PR Newswire
Mar-07-17 12:40PM	XTL Biopharmaceuticals Announces $2.8 Million Private Placement From Existing Investors PR Newswire
Mar-01-17 08:30AM	XTL Biopharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement PR Newswire
Feb-17-17 08:00AM	XTL Biopharmaceuticals Announces $2.5 Million Registered Direct Offering PR Newswire
Feb-13-17 09:08AM	XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome PR Newswire
Jan-25-17 08:30AM	XTL Biopharmaceuticals Announces Ratio Change of its Depositary Receipt Program PR Newswire
Jan-05-17 08:30AM	XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjögren's Syndrome PR Newswire
Dec-19-16 08:00AM	XTL Biopharmaceuticals to Present at Biotech Showcase PR Newswire
Dec-06-16 08:30AM	XTL Biopharmaceuticals Reports Third Quarter 2016 Financial Results & Provides Clinical and Operational Update PR Newswire
Nov-09-16 01:25PM	XTL Biopharmaceuticals Receives NASDAQ Notification Regarding Minimum Bid Requirements PR Newswire
Sep-27-16 08:30AM	XTL Biopharmaceuticals Reports Second Quarter 2016 Financial Results & Provides Clinical and Operational Update PR Newswire
Sep-07-16 08:32AM	XTL Biopharmaceuticals Announces the European Patent Office has Issued a Patent for its Lupus Drug hCDR1 PR Newswire
Sep-06-16 08:00AM	XTL Biopharmaceuticals to Present at Rodman & Renshaw Conference on September 12, 2016 PR Newswire
Aug-11-16 09:00AM	XTL Biopharmaceuticals Announces New Patent Filing in U.S. for Lupus Drug hCDR1 PR Newswire
Jun-02-16 09:11AM	Promising Lupus Drug From XTL Biopharmaceuticals Could Be Life Changer In Projected 4 Billion Dollar Market
Jun-01-16 08:30AM	XTL Biopharmaceuticals Reports First Quarter 2016 Financial Results & Provides Clinical and Operational Update PR Newswire
May-16-16 11:45AM	XTL Biopharmaceuticals to Present at ChinaBio Partnering Forum 2016 in Suzhou, China on May 19, 2016 PR Newswire
Apr-07-16 01:04PM	XTL BIOPHARMACEUTICALS LTD Financials
Mar-31-16 09:45AM	XTL Biopharmaceuticals Reports 2015 Financial Results & Provides Clinical and Operational Update PR Newswire
Mar-21-16 08:30AM	XTL Biopharmaceuticals Completes Phase 2 Trial Design for Lead Compound hCDR1 in the Treatment of Lupus PR Newswire
Mar-09-16 08:29AM	Lupus Thought Leader Daphna Paran, MD, Named Medical Director of XTL Biopharmaceuticals PR Newswire
Mar-02-16 09:00AM	XTL Biopharmaceuticals Expands Global IP Portfolio With Issued Patent in Hungary for Lupus Drug hCDR1 PR Newswire
Feb-22-16 09:02AM	XTL Biopharmaceuticals Receives European Medicines Agency's SME Status PR Newswire
Feb-10-16 08:30AM	XTL Biopharmaceuticals' Lupus Drug hCDR1 Granted Patent for Pharmaceutical Composition & Manufacturing Processes PR Newswire
Jan-27-16 08:30AM	XTL Biopharmaceuticals Joins Corporate Advisory Council of the Lupus Foundation of America PR Newswire
Jan-25-16 08:30AM	XTL Biopharmaceuticals Announces Encouraging Feedback from U.S. FDA on its Upcoming IND Filing for Lupus Drug hCDR1 PR Newswire
Jan-13-16 08:30AM	XTL Biopharmaceuticals Advances Formulation of its hCDR1 Drug for Clinical Trials in the Treatment of Lupus Through use of Cydex Pharmaceuticals' Captisol® PR Newswire
Jan-11-16 08:30AM	XTL Biopharmaceuticals Submits Protocol to Yeda for Advanced Clinical Trial of hCDR1 in the Treatment of Lupus PR Newswire
Dec-01-15 08:30AM	XTL Biopharmaceuticals Reports Third Quarter 2015 Results and Confirms Intention to Start Lupus Trial In 2016 PR Newswire
Nov-09-15 08:30AM	Cellect Biomed Announces Key Leadership Changes GlobeNewswire
Oct-28-15 09:00AM	Dr. Murray Urowitz, of the University of Toronto University Health Network, Provides Overview of an Analysis of Data from a Phase II Clinical Study of hCDR1 (Edratide) for the Treatment of Lupus PR Newswire
Oct-26-15 09:15AM	XTL Biopharmaceuticals to Present at BIO-Europe 2015 in Munich, Germany on November 3rd, 2015 PR Newswire
Oct-13-15 08:45AM	XTL Biopharmaceuticals Announces Agreement With Yeda Research and Development Company Ltd. to Amend License Agreement for Lupus Asset PR Newswire
Sep-17-15 11:40AM	XTL Biopharmaceuticals Ltd. Earnings Q2, 2015
Sep-03-15 09:00AM	XTL Biopharmaceuticals to Present at the Rodman & Renshaw 17th Annual Global Investment Conference on September 10th 2015 at the St. Regis Hotel in NYC PR Newswire
Sep-01-15 09:00AM	XTL Biopharmaceuticals Reports Second Quarter 2015 Results PR Newswire
Aug-26-15 09:00AM	XTL Announces Publication of Results of Phase 2 Study on hCDR1 (Edratide) in Patients with Active Systemic Lupus Erythematosus (SLE) in Lupus Science & Medicine PR Newswire
Jun-01-15 08:00AM	XTL Biopharmaceuticals Provides First Quarter 2015 Financial Update and Announces Focus of Efforts on its Lupus and Multiple Myeloma Assets PR Newswire
May-11-15 10:50AM	XTL Biopharmaceuticals to Present at IATI Biomed 2015 Conference PR Newswire
May-09-15 09:45AM	4 Speculative Biotechs With Huge Analyst Targets 24/7 Wall St.
May-08-15 09:35AM	XTL Biopharmaceuticals Aims To Tame Lupus, HC Wainwright Initiates At Buy
07:43AM	Coverage initiated on XTL Biopharma by H.C. Wainwright
Apr-28-15 07:45AM	XTL Biopharmaceuticals Provides Financial and Operational Update For the Full Year Ended December 31, 2014 PR Newswire
Mar-31-15 09:30AM	XTL Biopharmaceuticals Announces Pricing of $4.0 Million Registered Direct Offering PR Newswire
Feb-17-15 08:30AM	Biotech Investor Alex Rabinovich Increases Stake in XTL Biopharmaceuticals PR Newswire
Dec-30-14 12:23PM	XTL Biopharmaceuticals Annual General Meeting of Shareholders Appoints Two New Members to the Board of Directors PR Newswire
Dec-08-14 08:30AM	XTL Biopharmaceuticals Appoints Dr. Jonathan Schapiro MD and Dr. Dobroslav Melamed to the Board of Directors to Help Lead Development of its Clinical Assets PR Newswire
Dec-01-14 08:00AM	XTL Biopharmaceuticals Provides Financial and Operational Update For the Third Quarter of 2014 PR Newswire
Sep-02-14 12:09PM	XTL Biopharmaceuticals Provides Financial and Operational Update for the Second Quarter of 2014 PR Newswire
Jul-22-14 02:54PM	XTL Hopes To Begin Major Lupus Trial Next Year Seeking Alpha
Jul-16-14 09:18AM	XTL Bio's hCDR1 Compound Highlighted in Article Reviewing Potential Candidates for the Treatment of Lupus Published in Journal of Autoimmunity PR Newswire
Jun-12-14 08:00AM	XTL Biopharmaceuticals Receives Correspondence Regarding Nasdaq Listing Requirements PR Newswire
Jun-02-14 09:00AM	XTL Biopharmaceuticals Reports Financial and Operational Results for the First Quarter of 2014 PR Newswire
May-19-14 08:00AM	XTL Biopharmaceuticals Further Strengthens Team for Phase II Lupus Trial with Two Additional Experts PR Newswire
Apr-02-14 04:41PM	XTL Biopharmaceuticals Reports Financial and Operational Results for the Full Year Ended 2013 PR Newswire
Mar-25-14 08:00AM	XTL Biopharmaceuticals Retains Expert Consultants in Rheumatology for Phase II Lupus Trial PR Newswire
Jan-08-14 08:00AM	XTL Biopharmaceuticals In-licenses hCDR1, a Phase 2 Clinical Stage Asset for the Treatment of Lupus PR Newswire

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience